Sort   by:  
 Page size 
MetabolomicsNanoinducers-mediated Mitochondria-Selective Degradation Enhance T Cell Immunotherapy Against Multiple Cancers

Cancer immunotherapy utilizing cytotoxic T lymphocytes (CTLs) has demonstrated significant promise in clinical applications, but cancer immunosuppressive mechanisms hamper further progress in T cell immunotherapy. Here we show a correlation between cancer cell mitochondria content and their resis...

2025-03-13 | MTBLS12284 | MetaboLights
MetabolomicsTargeting secreted MDK-mediated tryptophan/kynurenine metabolism enhances DLL3 CAR T therapy for SCLC

Small cell lung cancer (SCLC) exhibits profound immunometabolic suppression that impairs antigen presentation and constrains immunotherapy efficacy. Through integrated multi-omics analyses of primary human SCLC tumors, we identified midkine (MDK) as a dominant tumor-secreted driver of immune evas...

2026-03-23 | MTBLS14116 | MetaboLights
TranscriptomicsT-bet-depended but IFN-gamma-independent genes in GVHD
Given T-bet is a master regulator for Th1 differentiation that produce IFN-gamma, underlining mechanisms accounted for the distinct GVHD outcomes caused by T-bet- versus IFN-gamma-deficient donor T cells are unclear. We hypothesize that GVHD is regulated by T-bet-dependent but IFN-gamma-independe...
ORGANISM(S): Mus musculus 
2014-10-30 | E-MTAB-2198 | biostudies-arrayexpress
TranscriptomicsIL-2 regulated genes in scurfy CD4+ T-cells
The goal of the study was to identify the genes which are regulated by Interleukin-2 in the CD4+ T cells of the scurfy mice during regulatory T-cell deficiency. Scurfy (Sf) mice bear a mutation in the forkhead box P3 (Foxp3) transcription factor, lack regulatory T-cells (Treg), develop multi-organ i...
ORGANISM(S): Mus musculus 
2012-09-18 | E-GEOD-23398 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of QUB HCT116 sensitive and resistant colorectal cancer time series
HCT116 parental, HCT116 5-FU resistant and HCT116 oxaliplatin resistant cells have been transiently treated with with their respective drug (5-FU or oxaliplatin) for 0, 6 12 or 24h in 3 independent experiments.
ORGANISM(S): Homo sapiens 
2006-01-01 | E-MEXP-390 | biostudies-arrayexpress
ProteomicsDeep phosphotyrosine characterization of mouse primary T cells using Broad Spectrum Optimization of Selective Triggering
Sequencing the tyrosine phosphoproteome using MS-based proteomics is challenging due to the low abundance of tyrosine phosphorylation in cells, a challenge compounded in scarce samples like primary cells or clinical samples. The broad-spectrum optimization of selective triggering (BOOST) method was ...
ORGANISM(S): Mus musculus (Mouse) 
2025-12-08 | PXD053863 | Pride
T cell Mus musculus Tmt 
TranscriptomicsZebrafish liver transcriptome in response to chronic treatment with environmentally relevant 5-FU
The fluoropyrimidine 5-fluorouracil (5-FU) is an antimetabolite that exerts its anticancer effects through inhibition of DNA synthesis and replication by inhibiting thymidylate synthase, and by incorporation of its metabolites into RNA and DNA. 5-FU is used in most of the currently applied regimens ...
ORGANISM(S): Danio rerio 
2015-04-23 | E-GEOD-63039 | biostudies-arrayexpress
ProteomicsIMPRINTS-CETSA, 5-FU in parental and 5-FU-resistant HCT15 cells
Parental and 5-fluorouracil (5-FU)-resistant HCT15 cells were treated with 5-FU or vehicle for 12h and assembled into an IMPRINTS-CETSA scheme with 6 different heating temperatures (37ºC, 47ºC, 50ºC, 52ºC, 54ºC, and 57ºC) with each set of samples heated at one temperature included in the same isobar...
ORGANISM(S): Homo Sapiens (human) 
2021-07-15 | PXD026472 | JPOST Repository
ProteomicsThe Prostacyclin Receptor is a NRF2-regulated Immune Checkpoint in CD8 T cells
Immune checkpoint inhibitor (ICI) therapies revitalize anti-cancer responses by intercepting protein-protein interactions between exhausted CD8 T (Tex) cells and cancer cells (e.g. PD-1:PD-L1). However, up to 50% of patients receiving ICIs relapse, warranting further interrogation of the underpinnin...
ORGANISM(S): Mus musculus (Mouse) 
2025-04-25 | PXD052688 | Pride
Adoptive cell therapy T cell exhaustion Immune checkpoint 
TranscriptomicsScRNA/TCR-seq of T cells from EMT6 tumors treated with aTGFb/aPD-L1
We performed 10x single cell RNA and VDJ sequencing on sorted T cells (7AAD- Calcein blue+ CD45+ THY1.1- TCRb+) in an orthotopic EMT6 tumor model 7 days after treatment initiation in four experimental groups: 1) Control 2) aPD-L1 3) aTGFb 4) aPD-L1 and aTGFb.
ORGANISM(S): Mus musculus 
2023-06-30 | E-MTAB-13073 | biostudies-arrayexpress
Sort   by:  
 Page size